Biomarkers of Leucine-Rich Repeat Kinase 2 (LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear Palsy - PubMed
2 hours ago
- #Progressive Supranuclear Palsy
- #LRRK2
- #Lysosomal Dysfunction
- The study investigated biomarkers of LRRK2 and lysosomal dysfunction in Progressive Supranuclear Palsy (PSP) using immunoblotting and multiplexed assays.
- Elevated total urine 22:6-BMP levels in PSP indicated lysosomal dysfunction and correlated with cerebrospinal fluid total LRRK2 levels.
- Carriers of the LRRK2 PD risk variant rs76904798 showed higher CSF total LRRK2 levels in PSP, though no group differences in total LRRK2 or pRab10Thr73 levels were found.
- Baseline monocyte total LRRK2 levels predicted one-year changes in PSP Rating Scale scores, suggesting its role in disease progression.
- Findings support targeting LRRK2 therapies for PSP patients stratified by genetic and biochemical markers to address lysosomal dysfunction.